Evidence map›Paper›PMID 36870337›Full record

ArticleThe lancet. Healthy longevity2023

The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia.

Emma Nichols, Richard Merrick, Simon I Hay, Dibya Himali, Jayandra J Himali, Sally Hunter, Hannah A D Keage, Caitlin S Latimer, Matthew R Scott, Jaimie D Steinmetz and 12 more

Open access · goldAbstract read
In one paragraph

Article in The lancet. Healthy longevity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. The path to treating multiple-etiology dementia: Combining vascular risk control and disease-modifying neurodegenerative therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  9. Cross-disease protein aggregate interactions in neurodegeneration: from molecular mechanisms to therapeutic strategies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Emma NicholsInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: eln1@uw.edu.
Richard MerrickCambridge Public Health, University of Cambridge, Cambridge, UK.
Simon I HayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Dibya HimaliFramingham Heart Study, Framingham, MA, USA.
Jayandra J HimaliFramingham Heart Study, Framingham, MA, USA; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Sally HunterCambridge Public Health, University of Cambridge, Cambridge, UK.
Hannah A D KeageCognitive Ageing and Impairment Neurosciences Lab, Justice and Society, University of South Australia, Adelaide, SA, Australia.
Caitlin S LatimerDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Matthew R ScottFramingham Heart Study, Framingham, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Jaimie D SteinmetzInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Jamie M WalkerDepartment of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mt Sinai, New York, NY, USA.
Stephen B WhartonSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Crystal D WiednerGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.
Paul K CraneDepartment of Medicine, University of Washington, Seattle, WA, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Lenore J LaunerLaboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Baltimore, MD, USA.
Fiona E MatthewsPopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Julie SchneiderRush Alzheimer's Disease Center, Chicago, IL, USA; Rush University Medical Center, Chicago, IL, USA.
Sudha SeshadriFramingham Heart Study, Framingham, MA, USA; Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA; Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Lon WhitePacific Health Research and Education Institute, Honolulu, HI, USA.
Carol BrayneCambridge Public Health, University of Cambridge, Cambridge, UK.
Theo VosInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
University of Washington · USUniversity of Cambridge · GBInstitute for Neurodegenerative Disorders · USNational Institute on Aging · USNewcastle University · GBPacific Health Research and Education Institute · USUniversity of Sheffield · GB

Funding

Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Linda Kathleen McEvoy · 2021 to 2026
$80.4M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN · 2019 to 2024
$29.8M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Thomas J. Grabowski · 2020 to 2026
$29.0M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes · 2021 to 2026
$24.0M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Epidemiology of Brain Aging in the Very OldU01AG019349 · NIA · KUAKINI MEDICAL CENTER · PI WHITE, LON RAY · 2001 to 2011
$14.0M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and ResilienceR01AG066524 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KASHANI, AMIR H, RAMACHANDRAN, VASAN S · 2020 to 2024
$9.7M
Department of HealthMedical Research Council G0400077Medical Research Council G0601022Medical Research Council G0900582Medical Research Council G9901400Medical Research Council U.1052.00.0013NHLBI NIH HHS 75N92019D00031NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01 HC005102NHLBI NIH HHS N01 HC025195NIA NIH HHS K08 AG065426NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066546NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017155NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG049607NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG062531NIA NIH HHS R01 AG066524NIA NIH HHS RF1 AG059421NIA NIH HHS U01 AG006781NIA NIH HHS U01 AG019349NIA NIH HHS U19 AG066567NINDS NIH HHS R01 NS017950NINDS NIH HHS R01 NS041265NINDS NIH HHS UF1 NS125513NINDS NIH HHS UH3 NS100599
6 · The paper itself

Abstract

backgroundPopulation-based autopsy studies provide valuable insights into the causes of dementia but are limited by sample size and restriction to specific populations. Harmonisation across studies increases statistical power and allows meaningful comparisons between studies. We aimed to harmonise neuropathology measures across studies and assess the prevalence, correlation, and co-occurrence of neuropathologies in the ageing population.

methodsWe combined data from six community-based autopsy cohorts in the US and the UK in a coordinated cross-sectional analysis. Among all decedents aged 80 years or older, we assessed 12 neuropathologies known to be associated with dementia: arteriolosclerosis, atherosclerosis, macroinfarcts, microinfarcts, lacunes, cerebral amyloid angiopathy, Braak neurofibrillary tangle stage, Consortium to Establish a Registry for Alzheimer's disease (CERAD) diffuse plaque score, CERAD neuritic plaque score, hippocampal sclerosis, limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC), and Lewy body pathology. We divided measures into three groups describing level of confidence (low, moderate, and high) in harmonisation. We described the prevalence, correlations, and co-occurrence of neuropathologies.

findingsThe cohorts included 4354 decedents aged 80 years or older with autopsy data. All cohorts included more women than men, with the exception of one study that only included men, and all cohorts included decedents at older ages (range of mean age at death across cohorts 88·0-91·6 years). Measures of Alzheimer's disease neuropathological change, Braak stage and CERAD scores, were in the high confidence category, whereas measures of vascular neuropathologies were in the low (arterioloscerosis, atherosclerosis, cerebral amyloid angiopathy, and lacunes) or moderate (macroinfarcts and microinfarcts) categories. Neuropathology prevalence and co-occurrence was high (2443 [91%] of 2695 participants had more than one of six key neuropathologies and 1106 [41%] of 2695 had three or more). Co-occurrence was strongly but not deterministically associated with dementia status. Vascular and Alzheimer's disease features clustered separately in correlation analyses, and LATE-NC had moderate associations with Alzheimer's disease measures (eg, Braak stage ρ=0·31 [95% CI 0·20-0·42]).

interpretationHigher variability and more inconsistency in the measurement of vascular neuropathologies compared with the measurement of Alzheimer's disease neuropathological change suggests the development of new frameworks for the measurement of vascular neuropathologies might be helpful. Results highlight the complexity and multi-morbidity of the brain pathologies that underlie dementia in older adults and suggest that prevention efforts and treatments should be multifaceted.

fundingGates Ventures.

Indexed as

Alzheimer DiseaseAtherosclerosisCerebral Amyloid AngiopathyLimbic EncephalitisAgedAged, 80 and overAutopsyCross-Sectional StudiesDementiaFemaleHumansMalePrevalenceTDP-43 Proteinopathies

Identifiers

PMID36870337
PMCPMC9977689
OpenAlexW4322722320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.